Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.

[1]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[2]  A. Sahin,et al.  Invasive Breast Carcinoma , 2014 .

[3]  P. V. van Diest,et al.  In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. V. van Diest,et al.  The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. , 2007, European journal of cancer.

[5]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[6]  C. Sotiriou,et al.  Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Baak,et al.  Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients , 2011, Breast Cancer Research and Treatment.

[8]  R. Mansel,et al.  Molecular detection of micro-metastasis in breast cancer. , 2002, Critical reviews in oncology/hematology.

[9]  P. V. van Diest,et al.  The multi‐center morphometric mammary carcinoma project (MMMCP) in the netherlands: Value of morphometrically assessed proliferation and differentiation , 1993, Journal of cellular biochemistry. Supplement.

[10]  D. Mavroudis,et al.  Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Quinn,et al.  The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables , 1990, The Journal of pathology.

[12]  C. Sotiriou,et al.  Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Ethier,et al.  Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Diest,et al.  Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer , 2010, Breast Cancer Research and Treatment.

[16]  Pierre-Marie Martin,et al.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.

[17]  J. Baak,et al.  HETEROGENEITY OF MITOTIC ACTIVITY IN BREAST CANCER , 1996, Histopathology.

[18]  J. Baak,et al.  Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Sabine Riethdorf,et al.  Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells , 2010, Annals of the New York Academy of Sciences.

[20]  Axel Hausen,et al.  Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers , 2009, Breast Cancer Research and Treatment.

[21]  D. Mavroudis,et al.  Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[23]  M. Daidone,et al.  Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.

[24]  J. Köllermann,et al.  Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Sauter,et al.  Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells , 2005, Clinical Cancer Research.

[26]  P. V. van Diest,et al.  Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.